Get the Stockscreener App
177.54
0.47%
-0.8468
Krystal Biotech Inc stock is traded at $177.54, with a volume of 70,149.
It is down -0.47% in the last 24 hours and up +13.99% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$178.39
Open:
$178.78
24h Volume:
70,149
Relative Volume:
0.27
Market Cap:
$5.07B
Revenue:
$241.52M
Net Income/Loss:
$52.37M
P/E Ratio:
99.74
EPS:
1.78
Net Cash Flow:
$58.06M
1W Performance:
-0.78%
1M Performance:
+13.99%
6M Performance:
-11.92%
1Y Performance:
-1.01%
1-Day Range:
$175.01
$178.78
1-Week Range:
$175.01
$187.11
52-Week Range:
$141.72
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
177.51 | 5.07B | 241.52M | 52.37M | 58.06M | 1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.64 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.36 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.21 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Keybank National Association OH - Defense World
How to Take Advantage of moves in (KRYS) - Stock Traders Daily
Bank of New York Mellon Corp Has $26.53 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait? - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from Analysts at Jefferies Financial Group - Defense World
Krystal Biotech initiated at buy at Jefferies on Vyjuvek, gene delivery tech - MSN
Krystal Biotech at TD Cowen Conference: Strategic Pipeline Progress By Investing.com - Investing.com Canada
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga India
Krystal Biotech’s Growth Potential: Strong Vyjuvek Launch and Promising Pipeline - TipRanks
Jefferies Initiates Krystal Biotech at Buy With $245 Price Target -March 05, 2025 at 07:22 am EST - Marketscreener.com
Jefferies Initiates Coverage of Krystal Biotech (KRYS) with Buy Recommendation - Nasdaq
Jefferies sets Krystal Biotech stock Buy rating, $245 target By Investing.com - Investing.com Australia
Krystal Biotech initiated with a Buy at Jefferies - TipRanks
Gene Therapy Market Top Companies Study-Krystal Biotech, Inc., - openPR
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Is the Market Bullish or Bearish on Krystal Biotech? - Benzinga
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug - Yahoo Finance
H.C. Wainwright maintains $221 target on Krystal Biotech stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $221 target on Krystal Biotech stock - Investing.com India
Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at HC Wainwright - Defense World
New York State Common Retirement Fund Has $3.66 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Principal Financial Group Inc. Purchases 3,727 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal gets positive EU regulatory opinion for Vyjuvek - MSN
Krystal Biotech chief accounting officer sells $131,415 in stock - Investing.com India
Krystal Biotech chief accounting officer sells $131,415 in stock By Investing.com - Investing.com UK
Solid Earnings Reflect Krystal Biotech's (NASDAQ:KRYS) Strength As A Business - Yahoo Finance
(KRYS) On The My Stocks Page - Stock Traders Daily
Krystal gets positive EU regulatory opinion for Vyjuvek (KRYS:NASDAQ) - Seeking Alpha
Krystal Biotech’s Vyjuvek: Anticipated European Approval and Strong Sales Projections Drive Buy Rating - TipRanks
European Panel Backs Approval of Topical Gene Therapy, Three Other New Medicines - Marketscreener.com
Krystal Biotech receives positive CHMP opinion for VYJUVEK - TipRanks
Krystal Biotech Gets CHMP Backing for Vyjuvek Approval - MarketWatch
Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
Illinois Municipal Retirement Fund Has $2.22 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
C WorldWide Group Holding A S Cuts Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
HC Wainwright Forecasts Krystal Biotech Q1 Earnings - MarketBeat
Chardan Capital Predicts Krystal Biotech FY2026 Earnings - MarketBeat
Krystal Biotech Q1 EPS Estimate Increased by William Blair - MarketBeat
Krystal Biotech to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Raised by State of New Jersey Common Pension Fund D - Defense World
Principal Financial Group Inc. Boosts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
William Blair Predicts Krystal Biotech Q1 Earnings - MarketBeat
Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know - MSN
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Why Krystal Biotech (KRYS) Might be Well Poised for a Surge - MSN
Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term - Nasdaq
Hussman Strategic Advisors Inc. Makes New $658,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Rhumbline Advisers Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Earnings Call: Optimism Amid Challenges - TipRanks
Brokers Issue Forecasts for Krystal Biotech FY2026 Earnings - Defense World
William Blair Raises Earnings Estimates for Krystal Biotech - Defense World
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):